Interviews

Vitaly Margulis, MD, discusses the Apa-RP study of adjuvant treatment consisting of apalutamide and androgen deprivation therapy in patients with high-risk localized prostate cancer.

Bradley McGregor, MD, discusses how ongoing trials hold the key for further breakthroughs in genitourinary cancer treatment.

Neel Bhatt, MD, discussed the importance of long-term patient monitoring following hematopoietic cell transplantation.

Mark A. Lewis, MD, discusses the exciting progress of dostarlimab in treating rectal cancer.

Bradley McGregor, MD, discusses background of the DAD trial evaluating sacituzumab govitecan-hziy in combination with enfortumab vedotin-ejfv for the treatment of patients with treatment-resistant metastatic urothelial carcinoma.

Anthony Conley, MD, discussed findings from a phase 1/2 study investigating the oncolytic virus AdAPT-001 in patients with solid tumors presented at ASCO 2024.

Stephen Williams, MD, MBA, MS, FACS, FACHE, discussed updates from the SunRISe-2 study investigating TAR-200 plus cetrelimab vs chemotherapy in muscle invasive bladder cancer.

Benjamin Lowentritt, MD, discussed findings from real-world analyses looking at enzalutamide or abiraterone vs apalutamide in patients with metastatic castration-sensitive prostate cancer.

Paolo Ghia, MD, PhD, discusses background of the phase 2 CAPTIVATE trial.

Finly Zachariah, MD, discusses the rationale behind implementing an AI mortality model at City of Hope, Duarte, California, which enhances the opportunity for patient-clinician discussions on end-of-life preferences, thereby boosting palliative care.

In an interview with Targeted Oncology, Sarah Sammons, MD, discussed an analysis of the DESTINY-Breast03 trial, highlighting the need for further research on trastuzumab deruxtecan in other breast cancer subtypes and solid tumors with brain metastases.

Anita Boyapati, PhD, discussed her research on the link between soluble BCMA and both disease burden and response to BCMA-targeted therapies in this patient population.

As part of its Speaking Out series, Patrick Wagner, MD, discusses safety concerns regarding oncolytic viral therapy.

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the importance of considering a drug's overall value beyond just its initial price per mg.

William Dale, MD, PhD, discusses the unmet needs of older patients requiring cancer treatment.

Premal Thaker, MD, discussed the ACCC Ovarian Quality of Care Project aiming to bridge the gap to improve ovarian cancer care for patients in the US.

Manmeet Ahluwalia, MD, MBA, FASCO, discusses the takeaways from a study which examined the impact of various therapies, including combination treatments, for patients with metastatic renal cell carcinoma.

Mikkael A. Sekeres MD, MS, provides insight on the approval of imetelstat for treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia.

Mazyar Shadman, discusses the mechanism of action of sonrotoclax and the phase 3 trial titled CELESTIAL-TNCLL, which is evaluating the agent for the treatment of patients with chronic lymphocytic leukemia.

Joseph Greer, PhD, discusses the late-breaking abstract from the 2024 ASCO Annual Meeting evaluating telehealth vs in-person palliative care for patients with advanced non-small cell lung cancer.

Lynn Schuchter, MD, 2023-2024 ASCO president, discusses her top abstracts from the annual meeting.

As part of its Speaking Out series, Patrick Wagner, MD, discusses eligibility and considerations for oncolytic viral therapies.

Alexa Simon Meara, MD, discussed how rheumatology and oncology can work together to improve outcomes for patients undergoing immunotherapy treatment for cancer.

Tarah Ballinger, MD, discusses findings from the phase 2 EAZ171 study of taxane-induced peripheral neuropathy in Black patients with breast cancer.

Peter Borchmann, MD, discusses the main takeaways from the GHSG HD21 study presented at the 2024 ASCO Annual Meeting.

In an interview with Targeted Oncology, Paolo Ghia, MD, PhD, discussed the 5-year results from the CAPTIVATE study in chronic lymphocytic leukemia and/or small lymphocytic lymphoma.

In an interview with Targeted Oncology, Aleksander L. Chojecki, MD, discussed findings from his research on hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib.

Doris Hansen, MD, discusses the efficacy of daratumumab, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone in newly diagnosed myeloma.

In an interview with Targeted Oncology, Daniel Nguyen, MD, PhD, further discussed the findings from this phase 2 trial and the potential of vibecotamab.

Lori J. Wirth, MD, discusses some of the emerging trends and developments that are on the horizon in the thyroid cancer space.